FIELD: biotechnology.
SUBSTANCE: group of inventions is described, including an antibody against B7-H3 or its antigen-binding fragment, a pharmaceutical composition for the treatment of diseases associated with B7-H3 positive cells, a nucleic acid molecule encoding the above-mentioned antibody or its antigen-binding fragment, a recombinant vector for the expression of an antibody or its antigen-binding fragment, a host cell transformed by a recombinant vector for the expression of an antibody or its antigen-binding fragment, a method for obtaining an antibody or its antigen-binding fragment and a method for the treatment of diseases associated with B7-H3 positive cells. In one embodiment, the antibody contains a variable region of a heavy chain, as shown in SEQ ID NO: 6 or 8, and a variable region of a light chain, as shown in SEQ ID NO: 7 or 9.
EFFECT: invention expands the arsenal of anti-B7-H3 agents.
14 cl, 5 dwg, 11 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODY TO CD3 AND ITS PHARMACEUTICAL USE | 2019 |
|
RU2802272C2 |
| ANTIBODY AGAINST BETA-AMYLOID, ANTIGEN-BINDING FRAGMENT OF SAID ANTIBODY, AND APPLICATION THEREOF | 2019 |
|
RU2777844C1 |
| ANTIBODY BINDING HUMAN IL-4R, ANTIGEN-BINDING FRAGMENT THEREOF, AND MEDICAL APPLICATION THEREOF | 2019 |
|
RU2779649C1 |
| BISPECIFIC PROTEIN | 2019 |
|
RU2784486C1 |
| ANTI-PCSK9 ANTIBODY, ITS ANTIGEN-BINDING DOMAIN AND MEDICAL APPLICATION THEREOF | 2016 |
|
RU2739208C2 |
| FUSED PROTEIN CONTAINING TGF-BETA RECEPTOR, AND ITS PHARMACEUTICAL USE | 2018 |
|
RU2776204C1 |
| ANTI-CLAUDIN 18.2 ANTIBODY AND USE THEREOF | 2020 |
|
RU2822550C2 |
| ANTIBODY TO PD-1, ITS ANTIGEN-BINDING FRAGMENT AND ITS PHARMACEUTICAL USE | 2020 |
|
RU2807484C2 |
| ANTIBODY TO CD40, ITS ANTIGENE-BINDING FRAGMENT AND ITS MEDICAL USE | 2018 |
|
RU2779128C2 |
| CONNECTIVE TISSUE GROWTH FACTOR ANTIBODY AND USE THEREOF | 2020 |
|
RU2819228C2 |
